Ralu Hinojos, MD
Family Medicine · El Paso, TXNPI 1992801294
Payments from drug & device makers
Across 109 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$212
- Lilly USA, LLC$176
- Merck$150
- Amarin Pharma, Inc.$127
- Pfizer$107
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$102
- plus $930 from 22 others
What the payments were for
- Food & beverage$1,77498%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $212 |
| Lilly USA, LLC | 11 | $176 |
| Merck | 9 | $150 |
| Amarin Pharma, Inc. | 7 | $127 |
| Pfizer | 7 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $102 |
| GSK | 7 | $96 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Kowa Pharmaceuticals America, Inc. | 6 | $77 |
| Radius Health, Inc. | 5 | $71 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Novo Nordisk | 4 | $51 |
| Boehringer Ingelheim | 3 | $49 |
| Aimmune Therapeutics, Inc. | 3 | $46 |
| Abbott | 2 | $45 |
| AstraZeneca | 3 | $45 |
| Novartis | 3 | $38 |
| Globus Medical | 1 | $35 |
| Amgen | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| Seqirus USA Inc | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$1,804 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 100 | $178,436 |
| JanuviaSitagliptin Phosphate | 143 | $173,152 |
| JanumetSitagliptin Phos/Metformin Hcl | 91 | $93,643 |
| ProliaDenosumab | 45 | $80,612 |
| EliquisApixaban | 78 | $69,994 |
| OzempicSemaglutide | 57 | $66,256 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $55,485 |
| Bydureon BciseExenatide Microspheres | 40 | $40,418 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $26,584 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $25,810 |
| FarxigaDapagliflozin Propanediol | 35 | $24,589 |
| TradjentaLinagliptin | 22 | $23,438 |
| XareltoRivaroxaban | 23 | $21,319 |
| VraylarCariprazine Hcl | 13 | $18,377 |
| MyrbetriqMirabegron | 23 | $16,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr, Dulera | $150 | $285,285263 claims |
| Lilly USA, LLCTrulicity | $176 | $178,436100 claims |
| AmgenProlia | $34 | $80,61245 claims |
| PfizerEliquis | $107 | $69,99478 claims |
| Novo NordiskOzempic | $51 | $66,25657 claims |
| AbbVieVraylar, Linzess | $212 | $34,13930 claims |
| AstraZenecaFarxiga | $45 | $24,58935 claims |
| Boehringer IngelheimTradjenta | $49 | $23,43822 claims |
| GSKTrelegy Ellipta | $96 | $12,79720 claims |
| Aimmune Therapeutics, Inc.Zenpep | $46 | $4,01819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in El Paso
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.